Experience

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $100 million initial public offering of common stock of Magenta…

Davis Polk advised the global coordinators and bookrunners in connection with the public offering by PagSeguro Digital Ltd. and Universo Online S.A., as selling shareholder, of an aggregate…

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Wix.com Ltd. of $385 million aggregate principal amount of its 0%…

Davis Polk advised the underwriters in connection with an initial public offering of 7,359,998 shares of common stock of Aptinyx Inc., at $16.00 per share (which includes the exercise in…

Davis Polk advised The Royal Bank of Scotland Group plc (RBSG), a public limited company incorporated under the laws of Scotland, in connection with its SEC-registered shelf takedown of $1…

Davis Polk advised the forward counterparties in connection with the execution of forward sale agreements on 15,282,392 shares of Entergy Corporation’s common stock (NYSE: ETR) in…

Davis Polk advised the sole book-running manager in connection with an SEC-registered common stock offering of 12,000,000 shares of common stock of Tellurian Inc. The net proceeds from…

Davis Polk advised the initial purchaser in connection with a Rule 144A and Regulation S offering by Sea Limited of $575 million aggregate principal amount of its 2.25% convertible…

Davis Polk advised Puxin Limited on its SEC-registered initial public offering of 8,280,000 American Depositary Shares, including the full exercise of the underwriters’ option to purchase 1…

Davis Polk is advising Roche on its acquisition of the outstanding shares of Foundation Medicine, Inc. not already owned by Roche at a price of $137.00 per share in cash. The transaction is…